[CLINICAL EVALUATION OF THERAPEUTIC EFFECTS OF 2 NEUROLEPTICS: R 2498 (TRIPERIDOL) AND 2028 MD (HALOANISONE)].
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D002090:Butyrophenones; D006801:Humans; D006993:Hypnotics and Sedatives; D001523:Mental Disorders; D014272:Trifluperidol
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D002090:Butyrophenones; D006993:Hypnotics and Sedatives; C005014:fluanisone; D014272:Trifluperidol
ANTIDEPRESSIVE AGENTS; HALOANISONE; HYPNOTICS AND SEDATIVES; MENTAL DISORDERS; TRIFLUPERIDOL
VALUTAZIONE CLINICA DEGLI EFFETTI TERAPEUTICI DI DUE NEUROLETTICI: LO R. 2498 (TRIPERIDOL) ED IL 2028 MD (HALOANISONE)